FROSTPHARMA ENTERS AGREEMENT WITH ADVICENNE FOR MARKETING AND DISTRIBUTION OF SIBNYAL® IN THE NORDIC

FrostPharma AB announces signature of an exclusive Distribution Agreement with Advicenne for marketing and distribution of Sibnayal® in Denmark, Finland, Norway, Iceland and Sweden.

Under the terms of the agreement, FrostPharma will receive the exclusive rights to distribute and market Sibnayal® for the treatment of distal renal tubular acidosis (dRTA) in the Nordic countries including Denmark, Finland, Norway, Iceland and Sweden. Sibnayal® received marketing authorisation in the European Union in May 2021 as the first and only label-approved drug for the treatment of Distal Renal Tubular Acidosis (dRTA) in adults, adolescents, and children aged one year and older.

Clas Lindbergson, Head of Business Development of FrostPharma stated: “We are proud to be partnering with Advicenne for the delivery of Sibnayal™ to patients and improve the lives of those suffering from Distal Renal Tubular Acidosis (dRTA). We look forward to working with them and to be continuing to expand our product portfolio in areas of high unmet need.”

Didier Laurens, Chief Executive Officer of Advicenne, commented: “We are delighted to be partnering with FrostPharma, a leader in the commercialization of a broad range of products across many disease areas. This is Advicenne’s third partnership for the commercialization of Sibnayal™ in just over a few weeks and is testament of our Company’s momentum. We have found in FrostPharma a partner that shares our same goal: delivering life-changing treatments for patients in areas of huge unmet need and we are looking forward to working together.”

About FrostPharma

FrostPharma is an entrepreneurial Swedish pharmaceutical company specializing in the commercialization of value-added products.

Since the start in 2017, FrostPharma has successfully commercialized a broad range of products across multiple disease areas, throughout the Nordic countries and beyond. The key to our success is using our extensive in-house commercialization competence to match specific patient and health care needs with relevant products.

For further information about FrostPharma, please visit www.frostpharma.com

About Advicenne

Advicenne (Euronext: ADVIC) is a specialty pharmaceutical company founded in 2007, specializing in the development of innovative treatments in Nephrology. Its lead product SibnayalTM (ADV 7103) has received its Marketing Approval for distal renal tubular acidosis in EU and the UK. ADV 7103 is currently in late-stage development in cystinuria in Europe and in dRTA and cystinuria in the US. Headquartered in Paris, Advicenne has been listed on the Euronext Paris stock exchange since 2017 and was cross-listed on the Euronext Brussels stock exchange in 2019. For additional information see: https://advicenne.com/

CONTACTS

FrostPharma AB Clas Lindbergson, Head of Business Development Phone: +46 706 581180 Email: clas.lindbergson@frostpharma.com

FrostPharma organisation announcement

During her tenure as CEO for FrostPharma AB, Cecilia Bröms-Thell has invested and prepared the FrostPharma business for accelerated growth while securing solid performance of the in-line portfolio. The Regulatory framework and the Commercial capabilities have been strengthened and FrostPharma is now in a position to leverage and maximise its pipe-line opportunities. Cecilia Bröms-Thell has however recently decided to explore new opportunities outside of FrostPharma why she has resigned as CEO. For a period of time Cecilia has however agreed to stay on as Chief Commercial Officer effective 1 january 2022. In this new role Cecilia Bröms-Thell will continue to strengthen the FrostPharma capabilities. “On behalf of FrostPharma and the Board I want to thank Cecilia Bröms-Thell for her significant contribution to the FrostPharma business as CEO and wish her good luck in her new role within FrostPharma as Chief Commercial Officer and later in her new role outside of Frost.”

From the 1st of January 2022 Fredrik Andersch take the role of FrostPharma CEO. Fredrik Andersch brings extensive international experience to FrostPharma from senior business positions at pharmaceutical companies such as AstraZeneca and Meda. Fredrik Andersch has a proven track-record of delivering strong growth through complex organisations both in a Nordic and international setting, such as Europe and Asia. With his background Fredrik Andersch also strengthen FrostPharma business development capabilities. The experience to drive growth through both portfolio and geographic expansion will further strengthen FrostPharma in its growth journey. As Fredrik consulted for FrostPharma in 2021 he has in-depth understanding of the organisation and business model, which secure business continuity during the transition. “On behalf of FrostPharma and the Board I want to wish Fredrik Andersch good luck in his role of CEO, and I look forward to working with him going forward.”

About Frost Pharma AB

FrostPharma AB is an entrepreneurial Swedish pharmaceutical company specialized in commercialization of products creating value. Since the start in 2017, FrostPharma has successfully commercialized a broad range of products across multiple disease areas, covering all Nordic countries and beyond. Key to success is the ability to match specific patient- and healthcare needs with relevant products in relation to our extensive in-house commercialization competence.

Tomas Guinchard

Chairman of the Board

Djupdykning - återvinningsbara doshjälpmedel

Henrik Alfredsson är Frost's vägvisare inom att ta fram återvinningsbara produkter. Nedan berättar han mer om våra doshjälpmedel i 100% återvinningsbar bioplast.

Vad är skillnaden på bioplast och vanlig plast som många artiklar är gjorda av idag?

De doshjälpmedel som är tillverkade av bioplast innehåller majsstärkelse för att minska andelen plast och därmed minska CO2-utsläpp. Vi använder den råvara som har högsta möjliga andel förnybart material för produktion.

På vilket sätt är våra doshjälpmedel ett bättre alternativ ur miljösynpunkt?

De är tillverkade i Sverige, CE-märkta, och kan återvinnas då de inte innehåller giftiga färger som förhindrar återvinning. Vi har även minskat mängden onödigt emballage som plastpåsar och använder miljövänliga kartonger för transport.

Vilka är de största fördelarna med våra doshjälpmedel i bioplast?

De är bättre för miljön och kan återvinnas. Även minskat utsläpp då de slipper transporteras från Kina där många alternativ kommer ifrån.

Vart hittar man våra doshjälpmedel?

Produkterna finns ute på merparten av samtliga apotek i Sverige och går även att beställa via Oriola. För övriga inköpskanaler kan ni kontakta oss direkt på info@frostpharma.com.